source
- FDA clears Bristol Myers' Zenbexus, first drug of a new class for advanced multiple myelomaThe FDA announced approval of an oral therapy from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug, iberdomide, will be marketed as Zenbexus and is intended to be used t…
- Zealand Pharma sells rights to rare blood cancer drug rusfertide for up to $100MZealand Pharma entered a royalty purchase and sale agreement with Royalty Pharma, receiving $50 million upfront and the possibility of an additional $50 million after one year. In exchange, Zealan…